Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03770260 · OUTCOME

Number of Participants Experiencing a Grade 3-5 Adverse Event (Dose Expansion)

Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment · Source last updated 2025-06-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Up to 2 years after Treatment

What was measured

Number of participants who experienced a grade 3-5 adverse event in the dose expansion group

Analysis population: Did not complete dose escalation phase to enroll to the dose expansion phase.

Groups in this outcome

Dose Expansion

Patients receive pevonedistat the maximum tolerated dose (MTD) as determined in the dose escalation phase by infusion ande ixazomib citrate 4 mg by mouth on days 1, 8, and 15 of each 28-day cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Dose Expansion0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
Number of participants who experienced a grade 3-5 adverse event in the dose expansion group
groups
  1. description
    Patients receive pevonedistat the maximum tolerated dose (MTD) as determined in the dose escalation phase by infusion ande ixazomib citrate 4 mg by mouth on days 1, 8, and 15 of each 28-day cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Dose Expansion
population Description
Did not complete dose escalation phase to enroll to the dose expansion phase.
reporting Status
POSTED
time Frame
Up to 2 years after Treatment
title
Number of Participants Experiencing a Grade 3-5 Adverse Event (Dose Expansion)
type
PRIMARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice